Formulating for cognitive health: mechanisms, doses and constraints

Cognitive health is the category where the distance between the marketing vocabulary and the specification is widest. “Nootropic”, “focus” and “clarity” describe a shelf position; they do not describe what a material does, how much of it you need, or whether it will survive your process. This walks through what is actually documented on the directory, grouped by mechanism rather than by claim.

Botanical adaptogens

Bacopin® is a bacopa extract standardized to bacosides A and B — one of the longest-studied materials in the category, and a good illustration of why the marker matters. Bacopa's activity is attributed to the bacoside fraction, so a bacopa extract that does not state a bacoside level is not a comparable material, whatever the botanical name on the label says.

The formulation constraints with bacopa are taste and dose. It is bitter, the studied intakes are not trivial, and both facts point towards capsules or a well-masked format rather than a beverage.

Phospholipids and membrane materials

BioPS® is phosphatidylserine, which sits in a different part of the category: a structural phospholipid rather than a plant extract with a marker compound. The specification question shifts accordingly — what matters is the PS content and the source, not a standardization to a secondary metabolite.

Phospholipids bring their own handling constraints. They are hygroscopic, they can be oxidatively sensitive, and a carrier-loaded grade behaves very differently in a blend from a neat one. This is a place where asking which grade the percentage refers to is not pedantry.

Mitochondrial cofactors

MitoSober® PQQ is pyrroloquinoline quinone, used at milligram-scale intakes — orders of magnitude below the botanicals above. That makes it easy to fit into a crowded formulation and correspondingly harder to blend uniformly: a material used at 10 mg in a 1 g serving needs real attention to premixing, and a content-uniformity failure at that ratio is not obvious until it is tested.

Caffeine, and why the source is a formulation decision

InnovaTea® is natural caffeine from tea. Chemically the caffeine is caffeine; the reason to specify a natural source is label positioning and, in some markets, what you are permitted to describe it as. Worth being clear-eyed about: this is a decision about the claim and the clean-label story, not about the pharmacology.

Eye health as an adjacent claim

Lutein and zeaxanthin materials such as OptiLut® frequently appear in cognitive and focus formulations as well as eye-health ones, and the two positionings carry different regulatory weight in different markets. The carotenoid content and the ester-versus-free-form question both affect your inclusion rate, so they are worth settling before the claim is written.

The constraints that decide it

• Total dose against format. Gram-scale botanicals and milligram-scale cofactors are not competing for the same space; a serving can usually carry one of the former and several of the latter.
• Content uniformity. Anything used below about 1% of the blend needs a premix strategy, not just a specification.
• Stability. Phospholipids and carotenoids both have real oxidative constraints; a shelf-life plan is part of the ingredient choice, not a later problem.
• Claim permission. Cognitive claims are among the most tightly constrained in most markets. What you may say bounds the formulation brief, not the other way round.

The ranked list for cognitive health carries the full documented set, and how to read a standardization statement covers what those assay figures are promising.

Nothing here is medical or regulatory advice. Confirm the position for your market and product category with your own regulatory advisers before formulating or labelling.